TABLE 8. Recommended vaccination schedule and intervals for persons who are at risk during an outbreak* attributable to a vaccine serogroup — Advisory Committee on Immunization Practices, United States, 2020.
| Age group | Serogroups A, C, W, and Y meningococcal conjugate vaccines MenACWY-D (Menactra, Sanofi Pasteur)† or MenACWY-CRM (Menveo, GlaxoSmithKline)§ or MenACWY-TT (MenQuadfi, Sanofi Pasteur)¶ | Serogroup B meningococcal vaccines MenB-FHbp (Trumenba, Pfizer) or MenB-4C (Bexsero, GlaxoSmithKline) |
|---|---|---|
| 2–23 mos |
Primary vaccination: MenACWY-D (aged ≥9 mos): 2 doses ≥12 wks apart
or MenACWY-CRM: If first dose at age
• 2 mos: 4 doses at 2, 4, 6, and 12 mos
• 3–6 mos: See catch-up schedule††
• 7–23 mos: 2 doses (second dose ≥12 wks after the first dose and after the 1st birthday) |
No recommendations for use of MenB vaccines in this population** |
| 2–9 yrs |
Primary vaccination: MenACWY-D§§
or MenACWY-CRM
or MenACWY-TT: 1 dose
Boosters (if previously vaccinated and identified as being at increased risk)¶¶:
• Aged <7 yrs: Single dose if ≥3 yrs since vaccination
• Aged ≥7 yrs: single dose if ≥5 yrs since vaccination |
No recommendations for use of MenB vaccines in this population** |
| ≥10 yrs | Primary vaccination: MenACWY-D or MenACWY-CRM or MenACWY-TT: 1 dose Boosters (if person previously vaccinated and identified as being at increased risk during an outbreak)¶¶: • Aged <7 yrs: Single dose if ≥3 yrs since vaccination • Aged ≥7 yrs: Single dose if ≥5 yrs since vaccination | Primary vaccination: MenB-FHbp: 3 doses at 0, 1–2, and 6 mos or MenB-4C: 2 doses ≥1 mo apart Boosters (if person previously vaccinated and identified as being at increased risk during an outbreak)***: Single dose if ≥1 yr after MenB primary series completion (≥6 mos interval might also be considered by public health professionals) Note: MenB-FHbp and MenB-4C are not interchangeable |
Abbreviations: DTaP = diphtheria and tetanus toxoids and acellular pertussis vaccine; MenACWY-CRM = meningococcal groups A, C, W, and Y oligosaccharide diphtheria CRM197 conjugate vaccine; MenACWY-D = meningococcal groups A, C, W, and Y polysaccharide diphtheria toxoid conjugate vaccine; MenACWY-TT = meningococcal groups A, C, W, and Y polysaccharide tetanus toxoid conjugate vaccine; MenB-4C = four-component meningococcal group B vaccine; MenB-FHbp = meningococcal group B factor H binding protein vaccine.
* Detailed recommendations on outbreak management are available at https://www.cdc.gov/meningococcal/downloads/meningococcal-outbreak-guidance.pdf.
† Licensed in the United States only for persons aged 9 months–55 years. Vaccination of persons aged ≥56 years is considered off-label.
§ Licensed in the United States only for persons aged 2 months–55 years. Vaccination of persons aged ≥56 years is considered off-label.
¶ Licensed in the United States only for persons aged ≥2 years.
** Licensed in the United States only for persons aged 10–25 years. Vaccination of persons aged ≥26 years is considered off-label.
†† If MenACWY-CRM is initiated at ages 3–6 months, catch-up vaccination includes doses at intervals of 8 weeks until the infant is aged ≥7 months, at which time an additional dose is administered at age ≥7 months, followed by a dose at least 12 weeks later and after the 1st birthday.
§§ MenACWY-D should be given either before or at the same time as DTaP to avoid interference with the immune response to meningococcal vaccine in children.
¶¶ Licensed in the United States only for a single booster dose for persons aged 15–55 years for MenACWY-D and MenACWY-CRM or aged ≥15 years for MenACWY-TT. Booster doses administered outside of these ages or administration of >1 booster dose are considered off-label.
*** Licensed in the United States only for a primary series. Administration of booster doses is considered off-label.